10-Q: Autolus Therapeutics Reports Progress in Obe-cel Development and Strategic Financing in Q1 2024

Autolus Therapeutics provides a first-quarter update highlighting the acceptance of its obe-cel marketing application by the EMA, a new manufacturing authorization, and significant financial activities.

Summary

• Autolus Therapeutics, a biopharmaceutical company, is developing programmed T cell therapies for cancer and autoimmune diseases.
• The company submitted a Biologics License Application (BLA) for its lead product candidate, obe-cel, for the treatment of relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) to the FDA in November 2023, with a target action date of November 16, 2024.
• In April 2024, the European Medicines Agency (EMA) accepted the obe-cel marketing authorization application (MAA) for r/r B-ALL.
• The company reported positive results from the FELIX Phase 1b/2 study, showing prolonged event-free survival and low immunotoxicity in r/r B-ALL patients.
• A Phase 1 study (CARLYSLE) for obe-cel in refractory systemic lupus erythematosus (SLE) patients is ongoing, with initial clinical data expected in late 2024.
• The company's manufacturing facility in Stevenage, United Kingdom, obtained a Manufacturers Importation Authorization (MIA) and a Good Manufacturing Practice certificate in March 2024.
• Autolus entered into strategic agreements with BioNTech in February 2024, including a securities purchase agreement, a registration rights agreement, a letter agreement, and a license and option agreement.
• The company completed an underwritten offering of 58,333,336 American Depositary Shares (ADSs) in February 2024, raising aggregate net proceeds of $326.8 million.
• As of March 31, 2024, Autolus had cash and cash equivalents of $758.5 million, which is expected to fund operations for at least the next twelve months.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the regulatory progress with obe-cel, the strategic collaboration with BioNTech, and the strong financial position. However, the net loss, the identified material weaknesses in internal controls, and the inherent risks of the industry temper the overall sentiment.

Positives

• Acceptance of the obe-cel MAA by the EMA represents a significant regulatory milestone.
• Receipt of MIA and GMP certification for the Stevenage manufacturing facility supports commercial readiness.
• The strategic collaboration with BioNTech provides substantial funding and potential future revenue streams.
• The successful underwritten offering significantly strengthened the company's financial position.
• The company has a strong cash position to fund operations through at least the next twelve months.
• Positive clinical data from the FELIX study supports the potential of obe-cel in r/r B-ALL.
• Enrollment in the CARLYSLE study for obe-cel in SLE is ongoing.
• Progress is being made in the MCARTY Phase 1 study for AUTO8 in multiple myeloma.
• The MAGNETO Phase 1 study for AUTO6NG in neuroblastoma is ongoing.

Negatives

• The company reported a net loss of $52.7 million for Q1 2024.
• Two material weaknesses in internal control over financial reporting were identified, one related to the misinterpretation of ASC Topic 740, Income Taxes, and another related to accounting for complex transactions.
• General and administrative expenses increased by 96% compared to Q1 2023.
• The company faces significant competition and rapidly changing technologies in the biopharmaceutical industry.

Risks

• The company may not receive regulatory approval for obe-cel or any of its other product candidates.
• Clinical trials may yield unexpected results or be delayed.
• The company may need to raise additional capital, which could dilute existing shareholders or require relinquishing rights to technologies or product candidates.
• The company may be unable to maintain its listing on the Nasdaq Global Select Market if it fails to meet reporting requirements.
• The identified material weaknesses in internal control over financial reporting could adversely affect the company's ability to report financial results accurately and timely.
• The company may not be able to successfully commercialize its product candidates, even if approved.
• Changes in foreign exchange rates could materially impact the company's financial results.
• The company is dependent on key personnel and third-party suppliers and manufacturers.
• The company may not be able to obtain or maintain adequate intellectual property protection for its product candidates.

Future Outlook

The company expects its existing cash and cash equivalents to be sufficient to fund operations for at least the next twelve months. Further long-term data from the FELIX study will be presented at ASCO and EHA in May and June 2024. Initial clinical data from the CARLYSLE study in SLE is expected in late 2024. Further updates from the MCARTY study are anticipated in the second half of 2024.

Management Comments

• The document contains certifications from the CEO and CFO but no specific management comments.

Industry Context

Autolus is part of the rapidly evolving field of cell and gene therapy, specifically focusing on CAR T cell therapies. This industry is characterized by high R&D investment, intense competition, and significant regulatory scrutiny. The company's focus on both cancer and autoimmune diseases positions it to address a broad range of unmet medical needs.

Comparison to Industry Standards

• Compared to industry leaders like Gilead Sciences (Kite Pharma) and Novartis, Autolus is still in the clinical development stage for its lead product candidate, obe-cel. Gilead's Yescarta and Tecartus, and Novartis' Kymriah are already approved for certain B-cell malignancies.
• Gilead reported Yescarta and Tecartus revenues of $359 million and $96 million respectively in Q1 2024.
• Novartis reported Kymriah revenues of $147 million in Q1 2024.
• Bristol Myers Squibb's Breyanzi and Abecma, CAR T cell therapies for B-cell malignancies, generated revenues of $105 million and $47 million respectively in Q1 2024.
• Autolus' collaboration with BioNTech is similar to other industry partnerships aimed at accelerating development and commercialization, such as the collaboration between Bristol Myers Squibb and 2seventy bio on Abecma.
• Autolus' reported net loss for Q1 2024 is not unusual for a clinical-stage biotechnology company, as both Gilead and Novartis also reported significant R&D expenses in their Q1 2024 reports.

Management Changes

Related Party Transactions

• The company entered into the Blackstone Agreements with BXLS V Autobahn L.P, (Blackstone) in November 2021, making Blackstone a related party.
• As of March 31, 2024, the carrying amount of the Blackstone Collaboration Agreement Liability was $188.5 million.
• The company entered into the BioNTech Agreements with BioNTech SE (BioNTech) in February 2024, making BioNTech a related party.
• As of March 31, 2024, the carrying amount of the BioNTech Liability was $40.0 million.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from future capital raises and the risks associated with the company's clinical development programs.
• Employees may be impacted by the company's growth and the need to hire additional personnel.
• Patients may benefit from the potential approval of obe-cel and other product candidates.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.
• Customers may be impacted by the availability and pricing of the company's products, if approved.

Next Steps

• The company will continue to work towards the potential approval and commercialization of obe-cel.
• Further clinical data from the FELIX, CARLYSLE, and MCARTY studies will be presented and analyzed.
• The company will continue to advance its pipeline of product candidates.
• The company will work to remediate the identified material weaknesses in internal control over financial reporting.
• The company plans to submit a MAA to the U.K. MHRA in the second half of 2024.

Key Dates

Keywords

CAR T cell therapy, cancer immunotherapy, autoimmune disease therapy, obe-cel, obecabtagene autoleucel, B-cell Acute Lymphoblastic Leukemia, relapsed/refractory, systemic lupus erythematosus, multiple myeloma, neuroblastoma, clinical trials, FDA, EMA, MHRA, manufacturing, commercialization, BioNTech, strategic collaboration, financing, underwritten offering